Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence

被引：1

作者：

Stamerra, Cosimo Andrea ^{[1
]}

Di Giosia, Paolo ^{[1
]}

Giorgini, Paolo ^{[1
]}

De Feo, Martina ^{[1
]}

Grassi, Davide ^{[1
]}

Ferri, Claudio ^{[1
]}

Sahebkar, Amirhossein ^{[2
,3
]}

机构：

[1] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy

[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran

[3] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Iran

来源：

JOURNAL OF NEUROSCIENCE RESEARCH | 2018年 / 96卷 / 05期

关键词：

atherosclerosis; statins; lipids; neurocognitive events; PCSK9; inhibitors; SECONDARY PREVENTION; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; BRAIN CHOLESTEROL; LDL-CHOLESTEROL; EVOLOCUMAB; HYPERCHOLESTEROLEMIA; EFFICACY; SAFETY; METAANALYSIS;

D O I：

10.1002/jnr.24199

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

页码：762 / 764

页数：3

共 35 条

[1] Hypercholesterolaemia and vascular dementia [J].

Appleton, Jason P. ;

Scutt, Polly ;

Sprigg, Nikola ;

Bath, Philip M. .

CLINICAL SCIENCE, 2017, 131 (14) :1561-1578

[2] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[3] Brain cholesterol:: Long secret life behind a barrier [J].

Björkhem, I ;

Meaney, S .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) :806-815

[4] A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia [J].

Blom, Dirk J. ;

Hala, Tomas ;

Bolognese, Michael ;

Lillestol, Michael J. ;

Toth, Phillip D. ;

Burgess, Lesley ;

Ceska, Richard ;

Roth, Eli ;

Koren, Michael J. ;

Ballantyne, Christie M. ;

Monsalvo, Maria Laura ;

Tsirtsonis, Kate ;

Kim, Jae B. ;

Scott, Rob ;

Wasserman, Scott M. ;

Stein, Evan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (19) :1809-1819

[5] Alzheimer's disease and cholesterol: The fat connection [J].

Canevari, Laura ;

Clark, John B. .

NEUROCHEMICAL RESEARCH, 2007, 32 (4-5) :739-750

[6] Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence [J].

Cicero, Arrigo F. G. ;

Tartagni, Elisa ;

Ertek, Sibel .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (06) :863-868

[7] Retargeting the management of hypercholesterolemia - focus on evolocumab [J].

Colletti, Alessandro ;

Derosa, Giuseppe ;

Cicero, Arrigo F. G. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 :1365-1376

[8]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

[9] Long-Term Effects of Secondary Prevention on Cognitive Function in Stroke Patients [J].

Douiri, Abdel ;

McKevitt, Christopher ;

Emmett, Eva S. ;

Rudd, Anthony G. ;

Wolfe, Charles D. A. .

CIRCULATION, 2013, 128 (12) :1341-1348

[10] Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapyA cognitive study of patients enrolled in the FOURIER trial [J].

Giugliano, Robert P. ;

Mach, Francois ;

Zavitz, Kenton ;

Kurtz, Christopher ;

Schneider, Jingjing ;

Wang, Huei ;

Keech, Anthony ;

Pedersen, Terje R. ;

Sabatine, Marc S. ;

Sever, Peter S. ;

Honarpour, Narimon ;

Wasserman, Scott M. ;

Ott, Brian R. .

CLINICAL CARDIOLOGY, 2017, 40 (02) :59-65

← 1 2 3 4 →